Results 91 to 100 of about 3,975,496 (251)

Concurrent Germline RB1 & Mosaic TP53 in a Child With Multiple Childhood Cancers

American Journal of Medical Genetics Part A, EarlyView.
ABSTRACT We report a patient with a pathogenic germline variant (PGV) in RB1 and somatic mosaicism for a pathogenic TP53 variant who developed three distinct types of childhood cancer: retinoblastoma, osteosarcoma, and myelodysplastic syndrome (MDS) before the age of 6 years.
Ole Haubjerg Nielsen, Ulrik Kristoffer Stoltze, Pernille Axél Gregersen, Marianne Hoffmann, Morten Lyng Høgild, Mette Klarskov Andersen, Lise Barlebo Ahlborn, Lisa Lyngsie Hjalgrim, Karin A. W. Wadt   +8 more
wiley   +1 more source

THERAPEUTIC EFFECTS OF WHOLE BRAIN RADIOTHERAPY WITH CARBOPLATIN AS RADIATION SENSITIZER IN MANAGEMENT OF BRAIN METASTASIS

Pakistan Armed Forces Medical Journal, 2013
Aim: To determine the efficacy of whole brain radiotherapy (WBRT) with carboplatin as radiation sensitizer in metastatic brain disease in our adult population. Study Design: Quasi-experimental study.
Dr Zeeshan Ahmed Alvi, Ahsan Mahmood ., Usman Ali ., Shahid Rasul ., Talha Maqsood ., Saira Ahmed ., Saima Ishtiaq ., Salman Arif .   +7 more
doaj   +2 more sources

In the context of the era of targeted therapy: evaluation of the survival benefits of different local treatment modalities for patients with 1–3 brain metastases from non-small cell lung cancer

Scientific Reports
Advances in molecular biology have extended survival for lung cancer patients with brain metastases. However, radiotherapy and surgery remain standard for non-small cell lung cancer (NSCLC) brain metastases.
Liang Sun, Haibin Chen, Zhi Yang, Liwen Li, Zhaohui ying, Yuanyuan Qu, Nanyang Tong, Caixing Sun, Liang Xia   +8 more
doaj   +1 more source

Biomarkers of Brain Damage Induced by Radiotherapy

Dose-Response, 2020
Radiotherapy remains currently a critical component for both primary and metastatic brain tumors either alone or in combination with surgery, chemotherapy, and molecularly targeted agents, while it could cause simultaneously normal brain tissue injury ...
Nahida Sultana, Chao Sun, Takanori Katsube, Bing Wang   +3 more
doaj   +1 more source

Radiosurgery or Fractionated Stereotactic Radiotherapy plus Whole-brain Radioherapy in Brain Oligometastases: A Long-term Analysis

, 2015
To analyze the outcome of patients with brain oligometastases treated by radiosurgery (SRS) or fractionated stereotactic radiotherapy (FSRT) after whole-brain radiotherapy (WBRT)
Mazzarella, Ciro, Ferro, Marica, Fersino, Sergio, Fiorentino, Alba, Frascino, Vincenzo, Valentini, Vincenzo, Azario, Luigi, Colosimo, Cesare, D'Agostino, Giuseppe Roberto, Autorino, Rosa, Pompucci, A, Balducci, Mario, Chiesa, Silvia, Mattiucci, Gian Carlo, Anile, Carmelo   +14 more
core  

Methods and results of locoregional treatment of brain metastases in patients with non-small cell lung cancer

Contemporary Oncology, 2016
This article presents methods and results of surgery and radiotherapy of brain metastases from non-small cell lung cancer (BMF-NSCLC). Patients with single BMF-NSCLC, with Karnofsky score ≥ 70 and controlled extracranial disease are the best candidates ...
Anna Patla, Tomasz Walasek, Jerzy Jakubowicz, Paweł Blecharz, Jerzy Władysław Mituś, Anna Mucha-Małecka, Marian Reinfuss   +6 more
doaj   +1 more source

Proton beam therapy in paediatric cancer: Anticipating the opening of the Australian Bragg Centre for Proton Therapy and Research

Journal of Medical Imaging and Radiation Oncology, EarlyView., 2023
Summary Proton Beam Therapy (PBT) has the potential to improve paediatric cancer care by reducing radiation exposure and thus long‐term toxicities. Ethical concerns and debates surrounding the treatment, such as eligibility and accessibility, are ongoing in Australia. The Australian Bragg Centre for Proton Therapy and Research (ABCPTR) (named after Sir
Jeremy Khong, Hui Tee, Peter Gorayski, Hien Le, Michael Penniment, Sophie Jessop, Jordan Hansford, Melanie Penfold, Julia Green, Kelly Skelton, Frank Saran   +10 more
wiley   +1 more source

Whole-Brain Radiotherapy for Brain Metastases: Evolution or Revolution?

, 2018
An estimated 20% of patients with cancer will develop brain metastases. Approximately 200,000 individuals in the United States alone receive whole-brain radiotherapy (WBRT) each year to treat brain metastases.
Jeffrey S. Wefel, Paul D. Brown, Anthony L. Asher, Manmeet S. Ahluwalia, Vinai Gondi, Osaama H. Khan   +5 more
core   +1 more source

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

British Journal of Clinical Pharmacology, EarlyView.
Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay, Amandine Manon, Hunter Stephens, S. Y. Amy Cheung, Bart de Keizer, Erik T. te Beek   +5 more
wiley   +1 more source

Role of radiotherapy in the management of brain metastases of NSCLC – Decision criteria in clinical routine

, 2021
Background: Whole brain radiotherapy (WBRT) is a common treatment option for brain metastases secondary to non-small cell lung cancer (NSCLC). Data from the QUARTZ trial suggest that WBRT can be omitted in selected patients and treated with optimal ...
Peeters, Stephanie T.H., McDonald, Fiona, Glatzer, Markus, Widder, Joachim, Geets, Xavier, Belderbos, José, Andratschke, Nicolaus, Nestle, Ursula, Guckenberger, Matthias, Van Houtte, Paul, Ramella, Sara, Slotman, Ben J., Lievens, Yolande, Dieckmann, Karin, Le Pechoux, Cecile, Dziadziuszko, Rafal, Putora, Paul Martin, Faivre-Finn, Corinne, Pöttgen, Christoph, De Ruysscher, Dirk, Ricardi, Umberto, Süveg, Krisztian, Troost, Esther G.C., Manapov, Farkhad   +23 more
core   +1 more source